The present invention relates to a composition for improving, preventing or treating an anxiety disorder, and a tranquilizing composition.

The invention relates to a method for producing an extract of a matrix of vegetable origin, particularly a plant, involving a solid-liquid extraction by means of an aqueous solution containing at least one, preferably agro-sourced, non-ionic amphiphilic compound, at a concentration at least equal to the minimum hydrotrope concentration thereof.

The present invention relates to a pharmaceutical composition and a food composition for preventing or ameliorating degenerative neurological disease comprising Poria cocos peel extract for preventing, or treating neurodegenerative disorders. Poria cocos peel extract which is the active ingredients contained in the composition of the present invention, has a memory ameliorating activity through inhibiting of acetylcholine esterase and a neuroprotective effect and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.

A method for producing a hop extract including filtering a hop-containing water at a temperature of 50° C. or higher, to give a hop extract. According to the method of the present invention, a hop extract having a high polyphenol concentration can be conveniently prepared, and is suitably used as raw materials for compositions for treating and/or ameliorating proteotoxin neutralization, inhibition of enamel decalcification, body fat modulation, protection of periodontal membranes, virus inactivation, inhibition of overexpression of thymic stromal lymphopoietin, symbiotic regeneration, obesity, anti-inflammation, inflammatory bowel disease, coronary artery disease, hyperuricemia, allergic diseases, digestive diseases, and the like.

The present invention relates to the pharmaceutical field, and in particular to a ginsenoside composition, and preparation method and use thereof. The ginsenoside composition comprises rare ginsenosides Rh4, Rk3, Rk1 and Rg5. By conducting a systematic research on the change in active ingredients during the steaming process of ginseng and applying response surface to design experiments so as to optimize the ginseng processing process, a processing method wherein there is the most significant change in ginsenoside ingredients relative to the original medicinal material, and especially a processing method for efficiently obtaining rare ginsenoside ingredients, is unexpectedly discovered in the present invention. Through later screening of pharmacological activities, the inventors further unexpectedly discovered that the processed ginseng product rich in rare ginsenosides has a significant efficacy in invigorating kidney yang.

The present disclosure relates to TGF-beta inhibition utilizing certain agents such as Artemisinin and antisense oligonucleotides including OT-101. The present invention also provides the composition comprising the said agents optionally along with one or more additional therapeutic agent, method of treating various viral diseases including COVID-19 and method of use involving said agents. The present invention further provides a substantially pure Artemisinin having a purity of more than 90%. The present invention also provides Artemisinin for use in the treatment of COVID-19. The present invention provides a process of extraction of artemisinin and a composition of matter comprising artemisinin. The present invention also provides a method of treating TGF-beta storm. The present invention also provides a method of use of anti-sense oligonucleotide by suppression of TGF-beta induced proteins including IL-6, TGFBIp.

The present invention relates to an application of a traditional Chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumonia.

This document relates to materials and methods for treating infections (e.g., ear infections and/or skin infections). For example, methods and materials for using a probiotic fermentation product to treat a veterinary animal (e.g., non-human mammal) having an infection and/or a complication associated with an infection (e.g., hearing loss caused by an ear infection) are provided.

An herbal combination composition can include, herbal extracts, including combinations of: Hyssopus officinalis, Zingiber officinale, Viola odorata, Ziziphus jujuba, Chamomile, and Ocimum tenuiflorum; pharmaceutical compositions, including combinations of: dextromethorphan, guaifenesin, acetaminophen, phenylephrine, diphenhydramine; polyethylene glycol; propylene glycol; poloxamer 407; ethylenediaminetetraacetic acid; methyl paraben; potassium sorbate; propyl paraben; xanthan gum; citric acid; anhydrous citric; and purified acetate buffered water. Also disclosed is a method for manufacture of an herbal combination composition, including dissolving herbal extracts, adding poloxamer, adding pharmaceutical compositions, adding acetate buffer, adding xanthan gum gel, adding acetate buffer.

A process is disclosed for extracting cannabinoids from plant materials. The process comprises providing a pressurizable extraction vessel having a rotatable drum with baffles, along with providing a solvent permeable filter bag. The plant material is placed within the filter bag, and the filter bag containing the plant material is placed within the extraction vessel. The extraction vessel is then filled with subcritical liquid carbon dioxide and rotated to so that the plant material is in contact with the liquid carbon dioxide. After a selected period of time, the liquid carbon dioxide solvent containing the cannabinoid extracted from the plant material is removed from the vessel, and sent to a separator. The separator separates the cannabinoid from the liquid carbon dioxide solvent.